Breckenridge Pharmaceutical, Inc.

Breckenridge Pharmaceutical, Inc. (United States) holds 1 active US FDA Type II Drug Master File and has DMF or CEP filings on record for 1 active ingredient. 37 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Breckenridge Pharmaceutical, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/breckenridge-pharmaceutical-inc

Overview

Breckenridge Pharmaceutical, Inc. is a subsidiary of Towa Pharmaceutical Co., Ltd., providing a variety of high-quality generic pharmaceutical products. The company focuses on delivering value and quality to meet the needs of patients and healthcare professionals.

Core services & business areas

Generic Pharmaceutical DistributionRegulatory AffairsContract Manufacturing

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Breckenridge Pharmaceutical, Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Breckenridge Pharmaceutical, Inc. holds 1 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • ETHACRYNIC ACID USPActive2013-09-03

FDA compliance signals

37 FDA enforcement records linked to this company.

  • recall — Class II2026-06-17

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

  • recall — Class II2026-06-17

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

  • recall — Class II2026-05-13

    CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

  • recall — Class II2025-12-10

    CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

  • recall — Class II2025-12-10

    CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

  • recall — Class II2025-11-05

    CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.

  • recall — Class II2025-09-17

    CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.

  • recall — Class II2025-08-20

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

  • recall — Class II2025-08-13

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

  • recall — Class II2025-07-16

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

  • recall — Class II2025-04-30

    CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

  • recall — Class II2025-04-30

    CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

  • recall — Class II2025-04-09

    CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.

  • recall — Class II2025-03-19

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

  • recall — Class II2025-03-19

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

  • recall — Class II2025-03-19

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

  • recall — Class II2025-01-01

    CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

  • recall — Class II2025-01-01

    CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

  • recall — Class II2024-10-23

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

  • recall — Class II2024-06-26

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

  • recall — Class II2024-05-15

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

  • recall — Class II2024-05-15

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

  • recall — Class II2024-05-15

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

  • recall — Class II2023-03-22

    CGMP Deviations: Potential risk of Cross Contamination

  • recall — Class II2023-03-22

    CGMP Deviations: Potential risk of Cross Contamination

  • recall — Class II2023-03-22

    CGMP Deviations: Potential risk of Cross Contamination

  • recall — Class II2023-03-22

    CGMP Deviations: Potential risk of Cross Contamination

  • recall — Class II2023-03-22

    CGMP Deviations: Potential risk of Cross Contamination

  • recall — Class II2023-03-22

    CGMP Deviations: Potential risk of Cross Contamination

  • recall — Class II2021-03-24

    Failed Impurities/Degradation Specifications: Out-of-Specification results obtained for unknown impurities during stability testing.

  • recall — Class II2020-03-25

    CGMP Deviations: During manufacturing Solifenacin Succinate Tablets might convert to Solifenacin Tartrate Tablets.

  • recall — Class II2020-03-25

    CGMP Deviations: During manufacturing Solifenacin Succinate Tablets might convert to Solifenacin Tartrate Tablets.

  • recall — Class III2020-03-04

    Failed Impurities/Degradation Specifications: Out-of-specification results obtained for impurities during stability testing.

  • recall — Class III2018-11-21

    Failed Stability Specifications: Out-of-Specification results obtained for particle size distribution during stability testing.

  • 4832017-02-21

    Late submission of 15-day report

  • recall — Class III2015-11-18

    Presence of Foreign Tablets/Capsules: one foreign capsule identified as omeprazole 10 mg was found in the bottle

  • warning_letter2010-02-09

    FDA Warning Letter (drug product)

For suppliers

Is this Breckenridge Pharmaceutical, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.